Accentuating the caveat emptor perspective with critical commentary on financial disclosure. I adopt a skeptical persona and look for chinks in the teflon coating of financial disclosure. My job is to identify financial warts. Perhaps a Black Swan. Disclosure: I do not hold positions in stocks mentioned for three trading days before or after blog post.
Thursday, June 29, 2006
Amarin Warm and Fuzzy
Amarin Corporation plc (Nasdaq:AMRN) keeps the corporate drum beating by announcing successful enrollment of enough candidates in the phase III clinical trials. The press release goes on to explain the potential merits/windfall that successful results may bring. No comment on when the trial may come to a close. No caveat’s that this is still a long way off. Just keeping everyone warm and fuzzy. Step right up and place your bets.